BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
With a market cap of 11.26B, BioMarin(BMRN) trades at $58.84. The stock has a price-to-earnings ratio of 33.10.
On 2026-03-04, BioMarin(BMRN) stock moved within a range of $58.00 to $60.32. With shares now at $58.84, the stock is trading +1.4% above its intraday low and -2.4% below the session's peak.
Trading volume for BioMarin(BMRN) stock has reached 1.79M, versus its average volume of 2.63M.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
BMRN News
In late February 2026, BioMarin Pharmaceutical received U.S. FDA approval for a supplemental Biologics License Application expanding PALYNZIQ’s use to pediatric...
Amicus ( (FOLD) ) just unveiled an announcement. On March 3, 2026, stockholders of Amicus Therapeutics approved the company’s acquisition by BioMarin Pharmaceu...
Barclays raised the firm’s price target on BioMarin (BMRN) to $105 from $80 and keeps an Overweight rating on the shares. Published first on TheFly – the ultim...
Analyst ratings
81%
of 26 ratingsMore BMRN News
BioMarin (BMRN) Pharmaceutical announced that the U.S. Food and Drug Administration, FDA, has approved the company’s supplemental Biologics License Application,...
Advertisement Event driven snapshot of BioMarin Pharmaceutical BioMarin Pharmaceutical (BMRN) is back on investor radars after recent share price moves, with...
BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics. The deal marks a major change for Amicus Therapeutics and its c...
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm sa...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.